These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 35612829)

  • 21. Immune Checkpoint Inhibitor-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis.
    Nielsen DL; Juhl CB; Nielsen OH; Chen IM; Herrmann J
    JAMA Oncol; 2024 Oct; 10(10):1390-1399. PubMed ID: 39172480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V
    Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury.
    Abu-Sbeih H; Tang T; Lu Y; Thirumurthi S; Altan M; Jazaeri AA; Dadu R; Coronel E; Wang Y
    J Immunother Cancer; 2019 Feb; 7(1):31. PubMed ID: 30728076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune Checkpoint Inhibitor-Associated Diabetes: A Single-Institution Experience.
    Byun DJ; Braunstein R; Flynn J; Zheng J; Lefkowitz RA; Kanbour S; Girotra M
    Diabetes Care; 2020 Dec; 43(12):3106-3109. PubMed ID: 33051330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A scoping review of vasculitis as an immune-related adverse event from checkpoint inhibitor therapy of cancer: Unraveling the complexities at the intersection of immunology and vascular pathology.
    Lee CM; Wang M; Rajkumar A; Calabrese C; Calabrese L
    Semin Arthritis Rheum; 2024 Jun; 66():152440. PubMed ID: 38579593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Precise medicine of programmed cell death-1/programmed cell death 1 ligand 1 inhibitor immunotherapy combined radiotherapy for inoperable advanced lung cancer: A protocol for systematic review and meta-analysis.
    Liu G; Lv X; Ding Y; Guo Y
    Medicine (Baltimore); 2021 Jun; 100(24):e26367. PubMed ID: 34128893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Mori K; Abufaraj M; Mostafaei H; Quhal F; Fajkovic H; Remzi M; Karakiewicz PI; Egawa S; Schmidinger M; Shariat SF; Gust KM
    Eur Urol; 2021 Jun; 79(6):783-792. PubMed ID: 33172722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens.
    Yao J; Li M; Zhang H; Ge Y; Weygant N; An G
    Int Immunopharmacol; 2020 Oct; 87():106770. PubMed ID: 32702598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
    Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
    Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature.
    Cosimati A; Rossi L; Didona D; Forcella C; Didona B
    J Oncol Pharm Pract; 2021 Apr; 27(3):727-733. PubMed ID: 32772795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
    De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
    J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.
    Aggarwal P
    Expert Opin Drug Saf; 2019 Jul; 18(7):623-633. PubMed ID: 31088310
    [No Abstract]   [Full Text] [Related]  

  • 34. Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review.
    Nakane T; Mitsuyama K; Yamauchi R; Kakuma T; Torimura T
    Kurume Med J; 2023 Jul; 68(2):43-52. PubMed ID: 37100606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hemidesmosomal Reactivity and Treatment Recommendations in Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid-A Retrospective, Monocentric Study.
    Schauer F; Rafei-Shamsabadi D; Mai S; Mai Y; Izumi K; Meiss F; Kiritsi D
    Front Immunol; 2022; 13():953546. PubMed ID: 35936009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two rare cases of bullous pemphigoid associated with immune checkpoint inhibitors.
    Mazumder A; Darji K; Smith K; Guo M
    BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36593610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-PD-1 and anti-PD-L1 drugs treatment-related adverse events for patients with cancer: Protocol for an overview of systematic reviews with meta-analyses.
    Li J; Liu M; Wang J; Liu Z; Xue J; Wang J; Jia J
    Medicine (Baltimore); 2019 Jul; 98(27):e16324. PubMed ID: 31277179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition.
    Hakroush S; Kopp SB; Tampe D; Gersmann AK; Korsten P; Zeisberg M; Tampe B
    Front Immunol; 2020; 11():624547. PubMed ID: 33552089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune Checkpoint Inhibitor-associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies.
    Tran AN; Wang M; Hundt M; Chugh R; Ohm J; Grimshaw A; Ciarleglio M; Hung KW; Proctor DD; Price CC; Laine L; Al-Bawardy B
    J Immunother; 2021 Oct; 44(8):325-334. PubMed ID: 34380976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic Treatment of Cutaneous Adverse Events After Immune Checkpoint Inhibitor Therapy: A Review.
    Brown AM; Masterson W; Lo J; Patel AB
    Dermatitis; 2023; 34(3):201-208. PubMed ID: 34405836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.